Sign in Join
Daily desk

News

Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.

Showing articles about oncology

3 stories

Split cards contrast PATHFINDER 2's 60.3% positive predictive value against NHS-Galleri's missed primary endpoint, framed as "two trials, one blood test, different verdicts."
🩺 Health Study

Two Nature Medicine Trials of a Multi-Cancer Blood Test Reach Different Verdicts on the Same Day

Published the same day in Nature Medicine, PATHFINDER 2 and the NHS-Galleri trial reach different verdicts on GRAIL's Galleri blood test: s…

EduFabTech · 1d ago · 5 min read
A blood-drop icon holding ten microRNA markers plus CA19-9 illustrates the PANXEON score, alongside its 86.8% stage I-II sensitivity, 96.8% specificity, and 1,785-patient cohort.
🩺 Health Study

A Blood-Based Score Combining Ten microRNAs and CA19-9 Flags Early Pancreatic Cancer in a 1,785-Person Study

A prospective 1,785-person study published in Nature Medicine on September 16, 2026, found that PANXEON — a blood test combining ten microR…

EduFabTech · 17 Sep 2026 · 4 min read
A bispecific antibody schematic bridges a T-cell and a myeloma cell, alongside headline stats showing 77.8% complete response, 92% two-year progression-free survival, and a hazard ratio of 0.15 for teclistamab.
🩺 Health Study

Randomized Trial Finds Teclistamab Outperforms Standard Early Treatment in High-Risk Smoldering Myeloma

A phase 2 trial in Nature Medicine found that early teclistamab treatment produced deep, durable remissions in high-risk smoldering myeloma…

EduFabTech · 15 Sep 2026 · 4 min read